SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare - Quaterly Results

25 May 2023 Evaluate
The sales slipped to Rs. 664.95 millions for the March 2023 quarter as against Rs. 728.73 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -289.25 millions as compared to Net Loss of Rs. -29.47 millions of corresponding quarter ended March 2022Operating Profit reported a sharp decline to 65.60 millions from 87.89 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 664.95 728.73 -8.75 2477.02 3569.52 -30.61 2477.02 3569.52 -30.61
Other Income 203.32 103.36 96.71 686.44 408.62 67.99 686.44 408.62 67.99
PBIDT 65.60 87.89 -25.36 246.44 625.49 -60.60 246.44 625.49 -60.60
Interest 66.08 17.32 281.52 208.25 90.54 130.01 208.25 90.54 130.01
PBDT -150.09 69.57 -315.74 -117.27 623.04 -118.82 -117.27 623.04 -118.82
Depreciation 119.79 102.92 16.39 465.48 348.18 33.69 465.48 348.18 33.69
PBT -269.88 -33.35 709.24 -582.75 274.86 -312.02 -582.75 274.86 -312.02
TAX 19.37 -3.88 -599.23 -87.93 73.27 -220.01 -87.93 73.27 -220.01
Deferred Tax 29.97 1.94 1444.85 -4.27 25.25 -116.91 -4.27 25.25 -116.91
PAT -289.25 -29.47 881.51 -494.82 201.59 -345.46 -494.82 201.59 -345.46
Equity 86.80 86.80 0.00 86.80 86.80 0.00 86.80 86.80 0.00
PBIDTM(%) 9.87 12.06 -18.20 9.95 17.52 -43.22 9.95 17.52 -43.22

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×